

RNS Number : 9560H
EKF Diagnostics Holdings PLC
26 June 2013

**EKF Diagnostics Holdings plc
("EKF" or "the Company")**

Analyst & Investor Teach-In

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, held a teach-in yesterday afternoon on EKF Molecular Diagnostics for analysts and investors.

The presentation given is available on EKF's corporate website:
www.ekfdiagnostics.com

No new material information was disclosed.

Enquiries:

EKF Diagnostics Holdings plc	Tel: 029 2071 0570
David Evans, Executive Chairman	Mob: 07740 084 452
Julian Baines, CEO	Mob: 07788 420 859

Canaccord Genuity Limited
Lucy Tilley / Henry Fitzgerald-O'Connor / **Tel: 020 7523 8000**
Julian Feneley

Walbrook PR Limited	Tel: 020 7933 8780
Paul McManus	Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com
Paul Cornelius	Mob: 07866 384 707 or paul.cornelius@walbrookpr.com

About EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in October 2010 for a maximum of £5.41m), Argutus Medical Limited (acquired in December 2010 for £2.18m) and Stanbio Laboratory L.P. (acquired in June 2011 for a maximum of US\$25.5m).

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focused on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In May 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

On the 4 March 2013, EKF announced the establishment of EKF Molecular Diagnostics Ltd to offer innovative products with the potential to change current DNA extraction and detection practices, enabling EKF to address the fast growing companion diagnostics market.

For more information please visit the website: www.ekfdiagnostics.com

This information is provided by RNS
The company news service from the London Stock Exchange

END

NRADMZVVZGFZM admin Analyst & Investor Teach-In 20989823 A Wed, 06/26/2013 - 17:43
Company Announcement - General EKF